Deep rTMS for Cannabis Use Disorder

Introduction and clinical context

The study Deep rTMS for Cannabis Use Disorder (ClinicalTrials.gov · em andamento) is part of the scientific research on the use of cannabinoids in cannabis use and addiction.

This area gathers studies on cannabis use disorder (CUD) and interventions to reduce problematic use — including behavioral, pharmacological and neuromodulation approaches, such as transcranial magnetic stimulation (rTMS). The content is scientific and public-health oriented: the goal is to inform about prevention, treatment and harm reduction, not to encourage consumption. The use of any substance should be assessed by healthcare professionals.

Understanding what science shows about the use of cannabinoids in cannabis use and addiction helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This study is registered on ClinicalTrials.gov and is ongoing. Deep transcranial magnetic stimulation (rTMS) in cannabis use disorder. As it is ongoing, there are no final published results yet. Following ongoing studies is important to anticipate the next evidence on the topic.

Mechanism of action and safety

Research in this area focuses on reducing problematic use, not on encouraging consumption. The approaches studied include behavioral, pharmacological and neuromodulation (rTMS) interventions, which act on the reward and craving circuits. From a safety standpoint, chronic high-dose cannabis use can lead to tolerance, withdrawal syndrome and, in vulnerable people, psychiatric risks. Management is multidisciplinary and individualized, led by healthcare professionals, with a focus on harm reduction.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (ClinicalTrials.gov · em andamento). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Is there treatment for problematic cannabis use?

Yes. Research assesses behavioral, pharmacological and neuromodulation interventions, led by professionals.

Does this content encourage consumption?

No. The focus is scientific and public-health oriented: prevention, treatment and harm reduction.